Investor Relations Home

Webcast ImageWebcast
NeuroDerm Q2 2016 Financial Results (Replay)
08/25/16 at 8:30 a.m. ET

NeuroDerm Q2 2016 Financial Results
Thursday, August 25, 2016 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system disorders, through proprietary formulations based on existing drugs that are intended to make a significant difference in patients' lives. NeuroDerm currently has four product candidates in development designed to treat moderate to severe Parkinson’s disease. The company designed its product candidates to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally.

Title
Download Documentation NeuroDerm July 2016 Corporate Presentation

Recent News

More >>
DateTitle 
08/25/16NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update
Company to host conference call and webcast today at 8:30 a.m. ET REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2016 and provided a corporate update. “We have been very productive in recent months advancing our clinical programs and moving closer toward our goal of providing a less inva... 
Printer Friendly Version
08/25/16NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease
Number of patients targeted for enrollment reduced based on observed and anticipated treatment effect REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it has initiated enrollment of Parkinson's disease (PD) patients in a Phase III efficacy trial (trial 007, named the "iNDiGO" trial) of ND0612L, the company’s low-dose continuous, subcutaneous... 
Printer Friendly Version
08/11/16NeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016
REHOVOT, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the second quarter of 2016 before the market opens on Thursday, August 25, 2016.  Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To access the call, dial 844-452-2810 (U.S.)... 
Printer Friendly Version

Upcoming Events | Past Events

More >>
There are currently no events scheduled.